Skip to Content

'
Timothy C Thompson, Ph.D.

Present Title & Affiliation

Primary Appointment

Professor, Department of Genitourinary Medical Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Director of Prostate Cancer Basic Science Research, Department of Genitourinary Medical Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Joan and Stanford Alexander Distinguished Chair for Prostate Cancer Research, Department of Genitourinary Medical Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1985 University of Colorado, Boulder, CO, PhD, Pharmaceutical Sciences-Pharmacology
1974 Indiana University, Bloomington, IN, BA, Biological Sciences

Postgraduate Training

1985-1988 Research Fellowship, Imperial Cancer Research Fund, London, United Kingdom

Experience/Service

Academic Appointments

Associate Professor, Urology, Cell Biology, Baylor College of Medicine, Houston, TX, 1992-1996
Assistant Professor, Urology, Baylor College of Medicine, Houston, TX, 1988-1992
Assistant Professor, Cell Biology, Baylor College of Medicine, Houston, TX, 1988-1992

Other Appointments/Responsibilities

Member, Residency Program Committee, Scott Department of Urology, Baylor College of Medicine, Houston, TX, 1991-2007
Executive Committee Member, NCI Specialized Program of Research Excellence (SPORE) for Prostate Cancer, Baylor College of Medicine, Houston, TX, 1991-2007
Member, (SPORE) For Prostate Cancer, Baylor College of Medicine Scientific Advisory Committee, Houston, TX, 1991-2007
Member, (SPORE) For Prostate Cancer, Baylor College of Medicine, Molecular Mechanisms Working Group, Houston, TX, 1991-2007
Member, Infectious Agents and Hazardous Chemicals Subcommittee, Baylor College of Medicine, Houston, TX, 1991-1992
Member, Research Committee, Scott Department of Urology, Baylor College of Medicine, Houston, TX, 1990-2007
Member, American Urologic Association/American Foundation for Urologic Disease Research Committee, Houston, TX, 1990-1992
Member, Baylor College of Medicine, Faculty Research and Fellowship Support Committee, Houston, TX, 1989-2007
Member, Veterans Administration Medical Center, Basic Science Subcommittee, Houston, TX, 1988-1991

Institutional Committee Activities

Reviewer, Mid-Tenure Review Committee of Dr. Min Sup Song, 6/2016-present

Honors and Awards

2014 MD Anderson Division of Cancer Medicine Team Science Award, University of Texas MD Anderson Cancer Center
2010 Annual Paul Jackson Rogers Lectureship, Scott and White Healthcare, Temple, Texas
2004 1st Place Basic Science Abstract, "Development of RTVP-1 Protein Therapy for Prostate Cancer", Baylor College of Medicine, 3rd Annual Cancer Center Symposium
1997 "Partner's in Courage", Achievement Award in Prostate Cancer for Excellence in Research, American Cancer Society

Selected Publications

Peer-Reviewed Original Research Articles

1. Karantanos T, Karanika S, Wang J, Yang G, Dobashi M, Park S, Ren C, Li L, Basourakos SP, Hoang A, Efstathiou E, Wang X, Troncoso P, Titus M, Broom B, Kim J, Corn PG, Logothetis CJ, Thompson TC. Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancer. Oncotarget. e-Pub 6/2016. PMID: 27331874.
2. Aparicio AM, Shen L, Tapia EL, Lu JF, Chen HC, Zhang J, Wu G, Wang X, Troncoso P, Corn P, Thompson TC, Broom B, Baggerly K, Maity SN, Logothetis CJ. Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers. Clin Cancer Res 22(6):1520-30, 3/15/2016. e-Pub 11/6/2015. PMCID: PMC4794379.
3. Sethna S, Chamakkala T, Gu X, Thompson TC, Cao G, Elliott MH, Finnemann SC. Regulation of Phagolysosomal Digestion by Caveolin-1 of the Retinal Pigment Epithelium is Essential for Vision. J Biol Chem. e-Pub 1/26/2016. PMID: 26814131.
4. Liu Y, Han X, Yu Y, Ding Y, Ni C, Liu W, Hou X, Li Z, Hou J, Shen D, Yin J, Zhang H, Thompson TC, Tan X, Cao G. A genetic polymorphism affects the risk and prognosis of renal cell carcinoma: association with follistatin-like protein 1 expression. Sci Rep 6:26689, 2016. e-Pub 5/26/2016. PMID: 27225192.
5. Reagan A, Gu X, Hauck SM, Ash JD, Cao G, Thompson TC, Elliott MH. Retinal Caveolin-1 Modulates Neuroprotective Signaling. Adv Exp Med Biol 854:411-8, 2016. PMID: 26427439.
6. Tu H, Gu J, Meng QH, Kim J, Davis JW, He Y, Wagar EA, Thompson TC, Logothetis CJ, Wu X. Mitochondrial DNA copy number in peripheral blood leukocytes and the aggressiveness of localized prostate cancer. Oncotarget 6(39):41988-96, 12/8/2015. e-Pub 10/26/2015. PMID: 26515605.
7. Cancer Genome Atlas Research Network. Electronic address: schultz@cbio.mskcc.org, Cancer Genome Atlas Research Network. The Molecular Taxonomy of Primary Prostate Cancer. Cell 163(4):1011-25, 11/5/2015. PMID: 26544944.
8. Yin J, Wang J, Pu R, Xin H, Li Z, Han X, Ding Y, Du Y, Liu W, Deng Y, Ji X, Wu M, Yu M, Zhang H, Wang H, Thompson TC, Ni W, Cao G. Hepatitis B virus combo mutations improve the prediction and active prophylaxis of hepatocellular carcinoma: a clinic-based cohort study. Cancer Prev Res (Phila) 8(10):978-88, 10/2015. e-Pub 8/19/2015. PMID: 26290395.
9. Kubo M, Satoh T, Tabata KI, Tsumura H, Iwamura M, Baba S, Thompson TC, Obata F. Enhanced central memory cluster of differentiation 8(+) and tumor antigen-specific T cells in prostate cancer patients receiving repeated in situ adenovirus-mediated suicide gene therapy. Mol Clin Oncol 3(3):515-521, 5/2015. e-Pub 2/2015. PMCID: PMC4471533.
10. Karantanos T, Evans CP, Tombal B, Thompson TC, Montironi R, Isaacs WB. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Eur Urol 67(3):470-9, 3/2015. e-Pub 10/2014. PMID: 25306226.
11. Karanika S, Karantanos T, Kurosaka S, Wang J, Hirayama T, Yang G, Park S, Golstov AA, Tanimoto R, Li L, Thompson TC. GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells. Mol Cancer 14:122, 2015. e-Pub 6/19/2015. PMCID: PMC4484888.
12. Thompson TC, Li L. New targets for resistant prostate cancer. Oncotarget 5(19):8816-7, 10/2014. PMCID: PMC4253400.
13. Li ML, Lin J, Hou JG, Xu L, Cui XG, Xu XX, Yu YW, Han X, Wang GM, Guo JM, Xu DF, Thompson TC, Cao GW, Zhang HW. Environmental and Psycho-social Factors Related to Prostate Cancer Risk in the Chinese Population: a Case-control Study. Biomed Environ Sci 27(9):707-717, 9/2014. PMID: 25256860.
14. Karanika S, Karantanos T, Li L, Corn PG, Thompson TC. DNA damage response and prostate cancer: defects, regulation and therapeutic implications. Oncogene 0. e-Pub 8/2014. PMCID: PMC4333141.
15. Li L, Chang W, Yang G, Ren C, Park S, Karantanos T, Karanika S, Wang J, Yin J, Shah PK, Takahiro H, Dobashi M, Zhang W, Efstathiou E, Maity SN, Aparicio AM, Li Ning Tapia EM, Troncoso P, Broom B, Xiao L, Lee HS, Lee JS, Corn PG, Navone N, Thompson TC. Targeting Poly(ADP-Ribose) Polymerase and the c-Myb-Regulated DNA Damage Response Pathway in Castration-Resistant Prostate Cancer. Sci Signal 7(326):ra47, 5/2014. e-Pub 5/2014. PMCID: PMC4135429.
16. Karantanos T, Tanimoto R, Edamura K, Hirayama T, Yang G, Golstov AA, Wang J, Kurosaka S, Park S, Thompson TC. Systemic GLIPR1-ΔTM protein as a novel therapeutic approach for prostate cancer. Int J Cancer 134(8):2003-13, 4/2014. e-Pub 11/2013. PMCID: PMC3942887.
17. Fujita T, Satoh T, Timme TL, Hirayama T, Zhu JX, Kusaka N, Naruishi K, Yang G, Goltsov A, Wang J, Vlachaki MT, Teh BS, Brian Butler E, Thompson TC. Combined therapeutic effects of adenoviral vector-mediated GLIPR1 gene therapy and radiotherapy in prostate and bladder cancer models. Urol Oncol 32(2):92-100, 2/2014. e-Pub 2/2013. PMCID: PMC3871954.
18. Karanika S, Karantanos T, Yin J, Li L, Thompson TC. Novel anti-androgen receptor signaling agents: understanding the mechanisms of resistance. Asian Journal of Urology:30-39, 2014.
19. Tan X, Wang Y, Han Y, Chang W, Su T, Hou J, Xu D, Yu Y, Ma W, Thompson TC, Cao G. Genetic variation in the GSTM3 promoter confer risk and prognosis of renal cell carcinoma by reducing gene expression. Br J Cancer 109(12):3105-15. doi: 10.1038/bjc.2013.669, 12/2013. e-Pub 10/2013. PMCID: PMC3859948.
20. Karantanos T, Corn PG, Thompson TC. Prostate cancer progression after androgen deprivation therapy: mechanicsms of castrate resistance and novel therapeutic approaches. Oncogene 32(49):doi: 10.1038/onc.2013.206, 12/2013. e-Pub 6/2013. PMCID: PMC3908870.
21. Ayala G, Morello M, Frolov A, You S, Li R, Rosati F, Bartolucci G, Danza G, Adam RM, Thompson TC, Lisanti MP, Freeman MR, Di Vizio D. Loss of caveolin-1 in prostate cancer stroma correlates with reduced relapse-free survival and is functionally relevant to tumor progression. J Pathol 231(1):77-87, 9/2013. e-Pub 7/2013. PMCID: PMC3978784.
22. Karantanos T, Thompson TC. GEMMs shine a light on resistance to androgen deprivation therapy for prostate cancer. Cancer Cell 24(1):11-13, 7/2013. PMCID: PMC3881957.
23. Li L, Yang G, Ren C, Tanimoto R, Hirayama T, Wang J, Hawke D, Kim SM, Lee JS, Goltsov AA, Park S, Ittmann MM, Troncoso P, Thompson TC. Glioma pathogenesis-related protein 1 induces prostate cancer cell death through Hsc70-mediated suppression of AURKA and TPX2. Mol Oncol 7(3):484-96, 6/2013. e-Pub 12/2012. PMCID: PMC3907183.
24. Tahir SA, Yang G, Goltsov A, Song KD, Ren C, Wang J, Chang W, Thompson TC. Caveolin-1LRP6 signaling module stimulates aerobic glycolysis in prostate cancer. Cancer Res 73(6):1900-11, 3/2013. e-Pub 1/2013. PMCID: PMC3688259.
25. Tahir SA, Kurosaka S, Tanimoto R, Goltsov AA, Park S, Thompson TC. Serum caveolin-1 as a biomarker of drug response and therapeutic target in association with tyrosine kinase inhibitor treatment in prostate cancer models. Cancer Biol Ther 14(2):117-26, 2/2013. e-Pub 10/2012. PMCID: PMC3571993.
26. Kuo SR, Tahir SA, Park S, Thompson TC, Coffield S, Frankel AE, Liu JS. Anti-caveolin-1 antibodies as anti-prostate cancer therapeutics. Hybridoma (Larchmt) 31(2):77-86, 4/2012. PMCID: PMC3326273.
27. Yang G, Goltsov AA, Ren C, Kurosaka S, Edamura K, Logothetis R, DeMayo FJ, Troncoso P, Blando J, DiGiovanni J, Thompson TC. Caveolin-1 upregulation contributes to c-myc-induced high-grade prostatic intraepithelial neoplasia and prostate cancer. Mol Cancer Res 10(2):218-29, 2/2012. e-Pub 12/2011. PMCID: PMC3908884.
28. Li L, Ren C, Yang G, Fattah EA, Goltsov AA, Kim SM, Lee JS, Park S, Demayo FJ, Ittmann MM, Troncoso P, Thompson TC. GLIPR1 suppressess prostate cancer through targeted oncoprotein destruction. Cancer Res 71(24):7694-704, 12/2011. e-Pub 10/2011. PMCID: PMC3813470.
29. Sonpavde G, Thompson TC, Jain RK, Ayala GE, Kurosaka S, Edamura K, Tabata K, Ren C, Goltsov AA, Mims MP, Hayes TG, Ittmann MM, Wheeler TM, Gee A, Miles BJ, Kadmon D. GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy. Clin Cancer Res 17(22):7174-82, 11/2011. e-Pub 9/2011. PMCID: PMC3865786.
30. Floryk D, Kurosaka S, Tanimoto R, Yang G, Goltsov A, Park S, Thompson TC. Castration-induced changes in mouse epididymal white adipose tissue molecular and cellular endocrinology. Mol Cell Endocrinol 345(1-2):58-67, 10/2011. e-Pub 7/2011. PMCID: PMC3867123.
31. Tabata K, Kurosaka S, Watanabe M, Edamura K, Satoh T, Yang G, Abdelfattah E, Wang J, Goltsov A, Floryk D, Thompson TC. Tumor growth and metastasis suppression by Glipr1 gene-modified macrophages in a metastatic prostate cancer model. Gene Ther 18(10):969-78, 10/2011. e-Pub 4/2011. PMCID: PMC3881531.
32. Thompson TC. Turning reciprocal feedback regulation into combination therapy. Cancer Cell 19(19):697-699, 6/2011. PMID: 21665144.
33. Gao Y, Ishiyama H, Sun M, Brinkman KL, Wang X, Zhu Z, Mai W, Huang Y, Floryk D, Ittmann M, Thompson TC, Butler EB, Xu B, The BS. The akylphospholipid, perifosine, radiosensitizes prostate cancer cells both in vitro and in vivo. Radiat Oncol(15):6-39, 4/2011.
34. Gao Y, Ishiyama H, Sun M, Brinkman KL, Wang X, Zhu J, Mai W, Huang Y, Floryk D, Ittmann M, Thompson TC, Butler EB, Xu B, Teh BS. The alkylphospholipid, perifosine, radiosensitizes prostate cancer cells both in vitro and in vivo. Radiat Oncol 6:39, 2011. e-Pub 4/2011. PMCID: PMC3096921.
35. Yang G, Park S, Cao G, Goltsov A, Ren C, Truong LD, Demayo F, Thompson TC. MMTV promoter-regulated caveolin-1 overexpression yields defective parenchymal epithelia in multiple exocrine organs of transgenic mice. Exp Mol Pathol 89(1):9-19, 8/2010. e-Pub 4/2010. PMCID: PMC3881545.
36. Thompson TC. Glioma pathogenesis-related protein 1: tumor-suppressor activities and therapeutic potential. Yonsei Med J 51(4):479-83, 7/2010. PMCID: PMC2880257.
37. Langeberg WJ, Tahir SA, Feng Z, Kwon EM, Ostrander EA, Thompson TC, Stanford JL. Association of caveolin-1 and -2 genetic variants and post-treatment serum caveolin-1 with prostate cancer risk and outcomes. Prostate 70(9):1020-35, 6/2010. PMCID: PMC2875326.
38. Thompson TC. Grappling with the androgen receptor: a new approach for treating advanced prostate cancer. Cancer Cell 17(6):525-6, 6/2010. PMCID: PMC3929402.
39. Thompson TC, Tahir SA, Li L, Watanabe M, Naruishi K, Yang G, Kadmon D, Logothetis CJ, Troncoso P, Ren C, Goltsov A, Park S. The role of caveolin-1 in prostate cancer: clinical implications. Prostate Cancer Prostatic Dis 13(1):6-11, 3/2010. e-Pub 7/2009. PMCID: PMC2887695.
40. Corn PG, Thompson TC. Identification of a novel prostate cancer biomarker, caveolin-1: Implications and potential clinical benefit. Cancer Manag Res 2:111-122, 2010. e-Pub 5/2010. PMCID: PMC3004586.
41. Tahir SA, Park S, Thompson TC. Caveolin-1 regulates VEGF-stimulated angiogenic activities in prostate cancer and endothelial cells. Cancer Biol Ther 8(23):2286-96, 12/2009. e-Pub 12/2009. PMCID: PMC2887683.
42. Li L, Ren C, Yang G, Goltsov AA, Tabata K, Thompson TC. Caveolin-1 promotes autoregulatory, Akt-mediated induction of cancer-promoting growth factors in prostate cancer cells. Mol Cancer Res 7(11):1781-91, 11/2009. e-Pub 11/2009. PMCID: PMC3881562.
43. Watanabe M, Yang G, Cao G, Tahir SA, Naruishi K, Tabata K, Fattah EA, Rajagopalan K, Timme TL, Park S, Kurosaka S, Edamura K, Tanimoto R, Demayo FJ, Goltsov AA, Thompson TC. Functional analysis of secreted caveolin-1 in mouse models of prostate cancer progression. Mol Cancer Res 7(9):1446-55, 9/2009. e-Pub 9/2009. PMCID: PMC2887686.
44. Tabata K, Watanabe M, Naruishi K, Edamura K, Satoh T, Yang G, Abdel Fattah E, Wang J, Goltsov A, Floryk D, Soni SD, Kadmon D, Thompson TC. Therapeutic effects of gelatin matrix-embedded IL-12 gene-modified macrophages in a mouse model of residual prostate cancer. Prostate Cancer Prostatic Dis 12(3):301-9, 2009. e-Pub 12/2008. PMID: 19104507.
45. Ayala GE, Dai H, Powell M, Li R, Ding Y, Wheeler TM, Shine D, Kadmon D, Thompson T, Miles BJ, Ittmann MM, Rowley D. Cancer-related axonogenesis and neurogenesis in prostate cancer. Clin Cancer Res 14(23):7593-603, 12/2008. PMID: 19047084.
46. Floryk D, Thompson TC. Antiproliferative effects of AVN944, a novel inosine 5-monophosphate dehydrogenase inhibitor, in prostate cancer cells. Int J Cancer 123(10):2294-302, 11/2008. PMCID: PMC2887704.
47. Ayala G, Yan J, Li R, Ding Y, Thompson TC, Mims MP, Hayes TG, MacDonnell V, Lynch RG, Frolov A, Miles BJ, Wheeler TM, Harper JW, Tsai MJ, Ittmann MM, Kadmon D. Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated akt. Clin Cancer Res 14(22):7511-8, 11/2008. PMCID: PMC2820291.
48. Floryk D, Thompson TC. Perifosine induces differentiation and cell death in prostate cancer cells. Cancer Lett 266(2):216-26, 8/2008. e-Pub 4/2008. PMCID: PMC2525810.
49. Wang H, Thompson TC. Gene-modified bone marrow cell therapy for prostate cancer. Gene Ther 15(10):787-96, 5/2008. e-Pub 4/2008. PMID: 18385769.
50. Yang G, Timme TL, Naruishi K, Fujita T, Fattah el MA, Cao G, Rajagopalan K, Rajocopolan K, Troung LD, Thompson TC. Mice with cav-1 gene disruption have benign stromal lesions and compromised epithelial differentiation. Exp Mol Pathol 84(2):131-40, 4/2008. e-Pub 8/2007. PMID: 18358473.
51. Tahir SA, Yang G, Goltsov AA, Watanabe M, Tabata K, Addai J, Fattah el MA, Kadmon D, Thompson TC. Tumor cell-secreted caveolin-1 has proangiogenic activities in prostate cancer. Cancer Res 68(3):731-9, 2/2008. PMID: 18245473.
52. Li L, Abdel Fattah E, Cao G, Ren C, Yang G, Goltsov AA, Chinault AC, Cai WW, Timme TL, Thompson TC. Glioma pathogenesis-related protein 1 exerts tumor suppressor activities through proapoptotic reactive oxygen species-c-Jun-NH2 kinase signaling. Cancer Res 68(2):434-43, 1/2008. PMID: 18199537.
53. Kiniwa Y, Miyahara Y, Wang HY, Peng W, Peng G, Wheeler TM, Thompson TC, Old LJ, Wang RF. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res 13(23):6947-58, 12/2007. PMID: 18056169.
54. Yang G, Addai J, Wheeler TM, Frolov A, Miles BJ, Kadmon D, Thompson TC. Correlative evidence that prostate cancer cell-derived caveolin-1 mediates angiogenesis. Hum Pathol 38(11):1688-95, 11/2007. PMID: 17707459.
55. Thompson TC. Suppression of tumor suppressors in prostate cancer: the emergence of a novel oncogenic pathway. Cancer Cell 12(5):405-7, 11/2007. PMID: 17996641.
56. Li R, Erdamar S, Dai H, Wheeler TM, Frolov A, Scardino PT, Thompson TC, Ayala GE. Forkhead protein FKHR and its phosphorylated form p-FKHR in human prostate cancer. Hum Pathol 38(10):1501-7, 10/2007. PMID: 17597184.
57. Wang H, Yang G, Timme TL, Fujita T, Naruishi K, Frolov A, Brenner MK, Kadmon D, Thompson TC. IL-12 gene-modified bone marrow cell therapy suppresses the development of experimental metastatic prostate cancer. Cancer Gene Ther 14(10):819-27, 10/2007. PMID: 17627292.
58. Nasu Y, Saika T, Ebara S, Kusaka N, Kaku H, Abarzua F, Manabe D, Thompson TC, Kumon H. Suicide gene therapy with adenoviral delivery of HSV-tK gene for patients with local recurrence of prostate cancer after hormonal therapy. Mol Ther 15(4):834-40, 4/2007. PMID: 17327829.
59. Thompson TC, Rodriguez R. Gene therapy prolongs PSA doubling time in prostate cancer patients. Mol Ther 15(3):442-3, 3/2007. PMID: 17311030.
60. Fujita T, Timme TL, Tabata K, Naruishi K, Kusaka N, Watanabe M, Abdelfattah E, Zhu JX, Ren C, Ren C, Yang G, Goltsov A, Wang H, Vlachaki MT, Teh BS, Butler EB, Thompson TC. Cooperative effects of adenoviral vector-mediated interleukin 12 gene therapy with radiotherapy in a preclinical model of metastatic prostate cancer. Gene Ther 14(3):227-36, 2/2007. PMID: 17024109.
61. Lai HH, Boone TB, Thompson TC, Smith CP, Somogyi GT. Using caveolin-1 knockout mouse to study impaired detrusor contractility and disrupted muscarinic activity in the aging bladder. Urology 69(2):407-11, 2/2007. PMID: 17320698.
62. Thompson TC. Exploiting the complex biology of prostate cancer. Cancer Biol Ther 5(11):1573-6, 11/2006. PMID: 17172813.
63. Ren C, Ren CH, Li L, Goltsov AA, Thompson TC. Identification and characterization of RTVP1/GLIPR1-like genes, a novel p53 target gene cluster. Genomics 88(2):163-72, 8/2006. PMID: 16714093.
64. Tahir SA, Frolov A, Hayes TG, Mims MP, Miles BJ, Lerner SP, Wheeler TM, Ayala G, Thompson TC, Kadmon D. Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort. Clin Cancer Res 12(16):4872-5, 8/2006. PMID: 16914574.
65. Naruishi K, Timme TL, Kusaka N, Fujita T, Yang G, Goltsov A, Satoh T, Ji X, Tian W, Abdelfattah E, Men T, Watanabe M, Tabata K, Thompson TC. Adenoviral vector-mediated RTVP-1 gene-modified tumor cell-based vaccine suppresses the development of experimental prostate cancer. Cancer Gene Ther 13(7):658-63, 7/2006. PMID: 16485011.
66. Ayala GE, Dai H, Tahir SA, Li R, Timme T, Ittmann M, Frolov A, Wheeler TM, Rowley D, Thompson TC. Stromal antiapoptotic paracrine loop in perineural invasion of prostatic carcinoma. Cancer Res 66(10):5159-64, 5/2006. PMID: 16707439.
67. Fujita T, Teh BS, Timme TL, Mai WY, Satoh T, Kusaka N, Naruishi K, Fattah EA, Aguilar-Cordova E, Butler EB, Thompson TC. Sustained long-term immune responses after in situ gene therapy combined with radiotherapy and hormonal therapy in prostate cancer patients. Int J Radiat Oncol Biol Phys 65(1):84-90, 5/2006. PMID: 16472937.
68. Ayala G, Satoh T, Li R, Shalev M, Gdor Y, Aguilar-Cordova E, Frolov A, Wheeler TM, Miles BJ, Rauen K, Teh BS, Butler EB, Thompson TC, Kadmon D. Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer. Mol Ther 13(4):716-28, 4/2006. PMID: 16480930.
69. Ayala GE, Dai H, Li R, Ittmann M, Thompson TC, Rowley D, Wheeler TM. Bystin in perineural invasion of prostate cancer. Prostate 66(3):266-72, 2/2006. PMID: 16245277.
70. Tetzlaff MT, Teh BS, Timme TL, Fujita T, Satoh T, Tabata K, Mai WY, Vlachaki MT, Amato RJ, Kadmon D, Miles BJ, Ayala G, Wheeler TM, Aguilar-Cordova E, Thompson TC, Butler EB. Expanding the therapeutic index of radiation therapy by combining in situ gene therapy in the treatment of prostate cancer. Technol Cancer Res Treat 5(1):23-36, 2/2006. PMID: 16417399.
71. Koh MS, Ittmann M, Kadmon D, Thompson TC, Leach FS. CDC4 gene expression as potential biomarker for targeted therapy in prostate cancer. Cancer Biol Ther 5(1):78-83, 1/2006. PMID: 16357515.
72. Saika T, Kusaka N, Mouraviev V, Satoh T, Kumon H, Timme Thompson TC. Therapeutic effects of adoptive splenocyte transfer following in situ AdIL-12 gene therapy in a mouse prostate cancer model. Cancer Gene Ther 13(1):91-8, 1/2006. PMID: 16052232.
73. Dai H, Li R, Wheeler T, Diaz de Vivar A, Frolov A, Tahir S, Agoulnik I, Thompson T, Rowley D, Ayala G. Pim-2 upregulation: biological implications associated with disease progression and perinueral invasion in prostate cancer. Prostate 65(3):276-86, 11/2005. PMID: 16015593.
74. Haqq C, Li R, Khodabakhsh D, Frolov A, Ginzinger D, Thompson T, Wheeler T, Carroll P, Ayala G. Ethnic and racial differences in prostate stromal estrogen receptor alpha. Prostate 65(2):101-9, 10/2005. PMID: 15880569.
75. Cyrus-David MS, Weinberg A, Thompson T, Kadmon D. The effect of statins on serum prostate specific antigen levels in a cohort of airline pilots: a preliminary report. J Urol 173(6):1923-5, 6/2005. PMID: 15879782.
76. Yang G, Timme TL, Frolov A, Wheeler TM, Thompson TC. Combined c-Myc and caveolin-1 expression in human prostate carcinoma predicts prostate carcinoma progression. Cancer 103(6):1186-94, 3/2005. PMID: 15712208.
77. Li L, Ittmann MM, Ayala G, Tsai MJ, Amato RJ, Wheeler TM, Miles BJ, Kadmon D, Thompson TC. The emerging role of the PI3-K-Akt pathway in prostate cancer progression. Prostate Cancer Prostatic Dis 8(2):108-18, 2005. PMID: 15724144.
78. Lai HH, Boone TB, Yang G, Smith CP, Kiss S, Thompson TC, Somogyi GT. Loss of caveolin-1 expression is associated with disruption of muscarinic cholinergic activities in the urinary bladder. Neurochem Int 45(8):1185-93, 12/2004. PMID: 15380628.
79. Ayala G, Thompson T, Yang G, Frolov A, Li R, Scardino P, Ohori M, Wheeler T, Harper W. High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin Cancer Res 10(19):6572-8, 10/2004. PMID: 15475446.
80. Rao XM, Tseng MT, Zheng X, Dong Y, Jamshidi-Parsian A, Thompson TC, Brenner MK, McMasters KM, Zhou HS. E1A-induced apoptosis does not prevent replication of adenoviruses with deletion of E1b in majority of infected cancer cells. Cancer Gene Ther 11(9):585-93, 9/2004. PMID: 15338010.
81. Ayala GE, Dai H, Ittmann M, Li R, Powell M, Frolov A, Wheeler TM, Thompson TC, Rowley D. Growth and survival mechanisms associated with perineural invasion in prostate cancer. Cancer Res 64(17):6082-90, 9/2004. PMID: 15342391.
82. Li R, Wheeler T, Dai H, Frolov A, Thompson T, Ayala G. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy. Am J Surg Pathol 28(7):928-34, 7/2004. PMID: 15223964.
83. Satoh T, Teh BS, Timme TL, Mai WY, Gdor Y, Kusaka N, Fujita T, Pramudji CK, Vlachaki MT, Ayala G, Wheeler T, Amato R, Miles BJ, Kadmon D, Butler EB, Thompson TC. Enhanced systemic T-cell activation after in situ gene therapy with radiotherapy in prostate cancer patients. Int J Radiat Oncol Biol Phys 59(2):562-71, 6/2004. PMID: 15145177.
84. Saika T, Satoh T, Kusaka N, Ebara S, Mouraviev VB, Timme TL, Thompson TC. Route of administration influences the antitumor effects of bone marrow-derived dendritic cells engineered to produce interleukin-12 in a metastatic mouse prostate cancer model. Cancer Gene Ther 11(5):317-24, 5/2004. PMID: 15044961.
85. Teh BS, Ayala G, Aguilar L, Mai WY, Timme TL, Vlachaki MT, Miles B, Kadmon D, Wheeler T, Caillouet J, Davis M, Carpenter LS, Lu HH, Chiu JK, Woo SY, Thompson T, Aguilar-Cordova E, Butler EB. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data. Int J Radiat Oncol Biol Phys 58(5):1520-9, 4/2004. PMID: 15050332.
86. Yang G, Addai J, Tian WH, Frolov A, Wheeler TM, Thompson TC. Reduced infiltration of class A scavenger receptor positive antigen-presenting cells is associated with prostate cancer progression. Cancer Res 64(6):2076-82, 3/2004. PMID: 15026346.
87. Ren C, Li L, Yang G, Timme TL, Goltsov A, Ren C, Ji X, Addai J, Luo H, Ittmann MM, Thompson TC. RTVP-1, a tumor suppressor inactivated by methylation in prostate cancer. Cancer Res 64(3):969-76, 2/2004. PMID: 14871827.
88. Teh BS, Ayala G, Auilar L, Mai W-Y, Timme TL, Vlachaki MT, Miles B, Kadmon D, Wheeler T, Caillouet J, Davis M, Carpenter LS, Lu HH, Chiu JK, Woo SY, Thompson TC, Aguilar-Cordova E and Butler EB. Phase I/II trial evaluating combined intensity modulated radiation therapy (IMRT) and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer--an interim report on PSA response and biopsy data. Int J Radiation Oncology Biol Phys 58:1520-1529, 2004.
89. Gdor Y, Timme TL, Kadmon D, Miles BJ, Thompson TC. Strategies for prostate cancer gene therapy. Am J Cancer 3:79-95, 2004.
90. Li L, Ren CH, Tahir SA, Ren C, Thompson TC. Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. Mol Cell Biol 23(24):9389-404, 12/2003. PMCID: PMC309640.
91. Satoh T, Saika T, Ebara S, Kusaka N, Timme TL, Yang G, Wang J, Mouraviev V, Cao G, Fattah el MA, Thompson TC. Macrophages transduced with an adenoviral vector expressing interleukin 12 suppress tumor growth and metastasis in a preclinical metastatic prostate cancer model. Cancer Res 63(22):7853-60, 11/2003. PMID: 14633713.
92. Tahir SA, Ren C, Timme TL, Gdor Y, Hoogeveen R, Morrisett JD, Frolov A, Ayala G, Wheeler TM, Thompson TC. Development of an immunoassay for serum caveolin-1: a novel biomarker for prostate cancer. Clin Cancer Res 9(10 Pt 1):3653-9, 9/2003. PMID: 14506154.
93. Wen Y, Giri D, Yan DH, Spohn B, Zinner RG, Xia W, Thompson TC, Matusik RJ, Hung MC. Prostate-specific antitumor activity by probasin promoter-directed p202 expression. Mol Carcinog 37(3):130-7, 7/2003. PMID: 12884364.
94. Zhao T, Rao XM, Xie X, Li L, Thompson TC, McMasters KM, Zhou HS. Adenovirus with insertion-mutated E1A selectively propagates in liver cancer cells and destroys tumors in vivo. Cancer Res 63(12):3073-8, 6/2003. PMID: 12810631.
95. Hillman GG, Xu M, Wang Y, Wright JL, Lu X, Kallinteris NL, Tekyi-Mensah S, Thompson TC, Mitchell MS, Forman JD. Radiation improves intratumoral gene therapy for induction of cancer vaccine in murine prostate carcinoma. Hum Gene Ther 14(8):763-75, 5/2003. PMID: 12804139.
96. Cao G, Yang G, Timme TL, Saika T, Truong LD, Satoh T, Goltsov A, Park SH, Men T, Kusaka N, Tian W, Ren C, Wang H, Kadmon D, Cai WW, Chinault AC, Boone TB, Bradley A, Thompson TC. Disruption of the caveolin-1 gene impairs renal calcium reabsorption and leads to hypercalciuria and urolithiasis. Am J Pathol 162(4):1241-8, 4/2003. PMCID: PMC1851223.
97. Timme TL, Satoh T, Tahir SA, Wang H, Teh BS, Butler EB, Miles BJ, Amato RJ, Kadmon D, Thompson TC. Therapeutic targets for metastatic prostate cancer. Curr Drug Targets 4(3):251-61, 4/2003. PMID: 12643475.
98. Satoh T, Yang G, Egawa S, Addai J, Frolov A, Kuwao S, Timme TL, Baba S, Thompson TC. Caveolin-1 expression is a predictor of recurrence-free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients. Cancer 97(5):1225-33, 3/2003. PMID: 12599229.
99. Satoh T, Timme TL, Saika T, Ebara S, Yang G, Wang J, Ren C, Kusaka N, Mouraviev V, Thompson TC. Adenoviral vector-mediated mRTVP-1 gene therapy for prostate cancer. Hum Gene Ther 14(2):91-101, 1/2003. PMID: 12614561.
100. Yang G, Ayala G, De Marzo A, Tian W, Frolov A, Wheeler TM,Thompson TC, Harper JW. Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin Cancer Res 8(11):3419-26, 11/2002. PMID: 12429629.
101. Mouraviev V, Li L, Tahir SA, Yang G, Timme TM, Goltsov A, Ren C, Satoh T, Wheeler TM, Ittmann MM, Miles BJ, Amato RJ, Kadmon D, Thompson TC. The role of caveolin-1 in androgen insensitive prostate cancer. J Urol 168(4 Pt 1):1589-96, 10/2002. PMID: 12352463.
102. Vlachaki MT, Hernandez-Garcia A, Ittmann M, Chhikara M, Aguilar LK, Zhu X, Teh BS, Butler EB, Woo S, Thompson TC, Barrera-Saldana H, Aguilar-Cordova E, The BS. Impact of preimmunization on adenoviral vector expression and toxicity in a subcutaneous mouse cancer model. Mol Ther 6(3):342-8, 9/2002. PMID: 12231170.
103. Gdor Y, Timme TL, Miles BJ, Kadmon D, Thompson TC. Gene therapy for prostate cancer. Expert Rev Anticancer Ther 2(3):309-321, 6/2002. PMID: 12113054.
104. Ren C, Li L, Goltsov AA, Timme TL, Tahir SA, Wang J, Garza L, Chinault AC, Thompson TC. mRTVP-1, a novel p53 target gene with proapoptotic activities. Mol Cell Biol 22(10):3345-57, 5/2002. PMCID: PMC133782.
105. Tyner SD, Venkatachalam S, Choi J, Jones S, Ghebranious N, Igelmann H, Lu X, Soron G, Cooper B, Brayton C, Park SH, Thompson T, Karsenty G, Bradley A, Donehower LA. p53 mutant mice that display early ageing-associated phenotypes. Nature 415(6867):45-53, 1/2002. PMID: 11780111.
106. Teh BS, Aguilar-Cordova E, Vlachaki MT, Aguilar L, Mai WY, Caillouet J, Davis M, Miles B, Kadmon D, Ayala G, Lu HH, Chiu JK, Carpenter LS, Woo SY, Grant WH, Wheeler T, Thompson TC, Butler EB. Combining radiotherapy with gene therapy (from the bench to the bedside): a novel treatment strategy for prostate cancer. Oncologist 7(5):458-66, 2002. PMID: 12401909.
107. Ebara S, Shimura S, Nasu Y, Kaku H, Kumon H, Yang G, Wang J, Timme TL, Aguilar-Cordova E, Thompson TC. Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters. Prostate Cancer Prostatic Dis 5(4):316-25, 2002. PMID: 12627218.
108. Pramudji C, Shimura S, Ebara S, Yang G, Wang J, Ren C, Yuan Y, Tahir SA, Timme TL, Thompson TC. In situ prostate cancer gene therapy using a novel adenoviral vector regulated by the caveolin-1 promoter. Clin Cancer Res 7(12):4272-9, 12/2001. PMID: 11751529.
109. Vlachaki MT, Chhikara M, Aguilar L, Zhu X, Chiu KJ, Woo S, Teh BS, Thompson TC, Butler EB, Aguilar-Cordova E. Enhanced therapeutic effect of multiple injections of HSV-TK + GCV gene therapy in combination with ionizing radiation in a mouse mammary tumor model. Int J Radiat Oncol Biol Phys 51(4):1008-17, 11/2001. PMID: 11704325.
110. Miles BJ, Shalev M, Aguilar-Cordova E, Timme TL, Lee HM, Yang G, Adler HL, Kernen K, Pramudji CK, Satoh T, Gdor Y, Ren C, Ayala G, Wheeler TM, Butler EB, Kadmon D, Thompson TC. Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum Gene Ther 12(16):1955-67, 11/2001. PMID: 11686937.
111. Cabeza-Arvelaiz Y, Thompson TC, Sepulveda JL, Chinault AC. LAPSER1: a novel candidate tumor suppressor gene from 10q24.3. Oncogene 20(46):6707-17, 10/2001. PMID: 11709705.
112. Cabeza-Arvelaiz Y, Sepulveda JL, Lebovitz RM, Thompson TC, Chinault AC. Functional identification of LZTS1 as a candidate prostate tumor suppressor gene on human chromosome 8p22. Oncogene 20(31):4169-79, 7/2001. PMID: 11464283.
113. Griffith TS, Kawakita M, Tian J, Ritchey J, Tartaglia J, Sehgal I, Thompson TC, Zhao W, Ratliff TL. Inhibition of murine prostate tumor growth and activation of immunoregulatory cells with recombinant canarypox viruses. J Natl Cancer Inst 93(13):998-1007, 7/2001. PMID: 11438565.
114. Li L, Yang G, Ebara S, Satoh T, Nasu Y, Timme TL, Ren C, Wang J, Tahir SA, Thompson TC. Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells. Cancer Res 61(11):4386-92, 6/2001. PMID: 11389065.
115. Thompson TC, Timme TL, Ebara S, Satoh T, Yang G, Wang J, Miles BJ, Ayala G, Wheeler TM, Kadmon D. In situ gene therapy for prostate cancer: immunomodulatory approaches. Expert Opin Biol Ther 1(3):481-95, 5/2001. PMID: 11727520.
116. Tahir SA, Yang G, Ebara S, Timme TL, Satoh T, Li L, Goltsov A, Ittmann M, Morrisett JD, Thompson TC. Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res 61(10):3882-5, 5/2001. PMID: 11358800.
117. Chhikara M, Huang H, Vlachaki MT, Zhu X, Teh B, Chiu KJ, Woo S, Berner B, Smith EO, Oberg KC, Aguilar LK, Thompson TC, Butler EB, Aguilar-Cordova E. Enhanced therapeutic effect of HSV-tk+GCV gene therapy and ionizing radiation for prostate cancer. Mol Ther 3(4):536-42, 4/2001. PMID: 11319915.
118. Sukin SW, Chhikara M, Zhu X, Ayala G, Aguilar LK, O'Brian Smith E, Miles BJ, Thompson TC, Kadmon D, Aguilar-Cordova E. In vivo surgical resection plus adjuvant gene therapy in the treatment of mammary and prostate cancer. Mol Ther 3(4):500-6, 4/2001. PMID: 11319910.
119. Shalev M, Thompson TC, Kadmon D, Ayala G, Kernen K, Miles BJ. Gene therapy for prostate cancer. Urology 57(1):8-16, 1/2001. PMID: 11164134.
120. Nasu Y, Bangma CH, Hull GW, Yang G, Wang J, Shimura S, McCurdy MA, Ebara S, Lee HM, Timme TL, Thompson TC. Combination gene therapy with adenoviral vector-mediated HSV-tk+GCV and IL-12 in an orthotopic mouse model for prostate cancer. Prostate Cancer Prostatic Dis 4(1):44-55, 2001. PMID: 12497062.
121. Teh BS, Aguillar-Cordova E, Kernen K, Chou CC, Shalev M, Vlachaki MT, Miles B, Kadmon D, Mai WY, Caillouet J, Davis M, Ayala G, Wheeler T, Brady J, Carpenter LS, Lu HH, Chiu JK, Woo SY, Thompson T, Butler EB. Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer--a preliminary report. Int J Radiat Oncol Biol Phys 51(3):605-613, 2001.
122. Thaller C, Shalev M, Frolov A, Eichele G, Thompson TC, Williams RH, Dillioglugil O, Kadmon D. Fenretinide therapy in prostate cancer: effects on tissue and serum retinoid concentration. J Clin Oncol 18(22):3804-8, 11/15/2000. PMID: 11078493.
123. Shimura S, Yang G, Ebara S, Wheeler TM, Frolov A, Thompson TC. Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. Cancer Res 60(20):5857-61, 10/15/2000. PMID: 11059783.
124. Shalev M, Thompson TC, Frolov A, Lippman SM, Hong WK, Fritsche H, Kadmon D. Effect of 13-cis-retinoic acid on serum prostate-specific antigen levels in patients with recurrent prostate cancer after radical prostatectomy. Clin Cancer Res 6(10):3845-9, 10/2000. PMID: 11051228.
125. Hull GW, Mccurdy MA, Nasu Y, Bangma CH, Yang G, Shimura S, Lee HM, Wang J, Albani J, Ebara S, Sato T, Timme TL, Thompson TC. Prostate cancer gene therapy: comparison of adenovirus-mediated expression of interleukin 12 with interleukin 12 plus B7-1 for in situ gene therapy and gene-modified, cell-based vaccines. Clin Cancer Res 6(10):4101-9, 10/2000. PMID: 11051263.
126. Yang G, Addai J, Ittmann M, Wheeler TM, Thompson TC. Elevated caveolin-1 levels in African-American versus white-American prostate cancer. Clin Cancer Res 6(9):3430-3, 9/2000. PMID: 10999725.
127. Timme TL, Goltsov A, Tahir S, Li L, Wang J, Ren C, Johnston RN, Thompson TC. Caveolin-1 is regulated by c-myc and suppresses c-myc-induced apoptosis. Oncogene 19(29):3256-65, 7/6/2000. PMID: 10918582.
128. Ayala G, Wheeler TM, Shalev M, Thompson TC, Miles B, Aguilar-Cordova E, Chakraborty S, Kadmon D. Cytopathic effect of in situ gene therapy in prostate cancer. Hum Pathol 31(7):866-70, 7/2000. PMID: 10923926.
129. Thompson TC, Timme TL, Park SH, Yang G, Ren C. Mouse prostate reconstitution model system: A series of in vivo and in vitro models for benign and malignant prostatic disease. Prostate 43(4):248-54, 6/1/2000. PMID: 10861743.
130. Shalev M, Kadmon D, Teh BS, Butler EB, Aguilar-Cordova E, Thompson TC, Herman JR, Adler HL, Scardino PT, Miles BJ. Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer. J Urol 163(6):1747-50, 6/2000. PMID: 10799174.
131. Kwabi-Addo B, Thompson TC, Ittmann M. Absence of PTEN/MMAC1 pseudogene in mice. DNA Cell Biol 19(5):301-5, 5/2000. PMID: 10855797.
132. Stepanova L, Yang G, DeMayo F, Wheeler TM, Finegold M, Thompson TC, Harper JW. Induction of human Cdc37 in prostate cancer correlates with the ability of targeted Cdc37 expression to promote prostatic hyperplasia. Oncogene 19(18):2186-93, 4/27/2000. PMID: 10822368.
133. Lee HM, Timme TL, Thompson TC. Resistance to lysis by cytotoxic T cells: a dominant effect in metastatic mouse prostate cancer cells. Cancer Res 60(7):1927-33, 4/1/2000. PMID: 10766182.
134. Shalev M, Miles BJ, Thompson TC, Ayala G, Butler EB, Aguilar-Cordova E, Kadmon D. Suicide gene therapy for prostate cancer using a replication-deficient adenovirus containing the herpesvirus thymidine kinase gene. World J Urol 18(2):125-9, 4/2000. PMID: 10854147.
135. Lotan Y, Xu XC, Shalev M, Lotan R, Williams R, Wheeler TM, Thompson TC, Kadmon D. Differential expression of nuclear retinoid receptors in normal and malignant prostates. J Clin Oncol 18(1):116-21, 1/2000. PMID: 10623701.
136. Shaker MR, Yang G, Timme TL, Park SH, Kadmon D, Ren C, Ji X, Lee HM, Sehgal I, Anzano M, Sporn MB, Thompson TC. Dietary 4-HPR suppresses the development of bone metastasis in vivo in a mouse model of prostate cancer progression. Clin Exp Metastasis 18(5):429-38, 2000. PMID: 11467776.
137. Paielli DL, Wing MS, Rogulski KR, Gilbert JD, Kolozsvary A, Kim JH, Thompson TX and Freytag SG. Evaluation of the biodistribution, persistence, toxicity and potential of germ line transmission of a replication-competent human adenovirus following intraprostatic administration in the mouse. Mol Ther 1:263-274, 2000.
138. Thompson TC, Yang G. Regulation of apoptosis in prostatic disease. Prostate 9(Suppl):25-8, 2000. PMID: 11056499.
139. Yang G, Truong LD, Wheeler TM, Thompson TC. Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. Cancer Res 59(22):5719-23, 11/1999. PMID: 10582690.
140. Thompson TC, Timme TL, Li L, Goltsov A. Caveolin-1, a metastasis-related gene that promotes cell survival in prostate cancer. Apoptosis 4(4):233-7, 8/1999. PMID: 14634273.
141. Erdamar S, Yang G, Harper JW, Lu X, Kattan MW, Thompson TC, Wheeler TM. Levels of expression of p27KIP1 protein in human prostate and prostate cancer: an immunohistochemical analysis. Mod Pathol 12(8):751-5, 8/1999. PMID: 10463475.
142. Bangma CH, Nasu Y, Ren C, Thompson TC. Metastasis-related genes in prostate cancer. Semin Oncol 26(4):422-7, 8/1999. PMID: 10482184.
143. Herman JR, Adler HL, Aguilar-Cordova E, Rojas-Martinez A, Woo S, Timme TL, Wheeler TM, Thompson TC, Scardino PT. In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum Gene Ther 10(7):1239-49, 5/1/1999. PMID: 10340555.
144. Nasu Y, Bangma CH, Hull GW, Lee HM, Hu J, Wang J, McCurdy MA, Shimura S, Yang G, Timme TL, Thompson TC. Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model. Gene Ther 6(3):338-49, 3/1999. PMID: 10435084.
145. Sehgal I, Thompson TC. Novel regulation of type IV collagenase (matrix metalloproteinase-9 and -2) activities by transforming growth factor-beta1 in human prostate cancer cell lines. Mol Biol Cell 10(2):407-16, 2/1999. PMID: 9950685.
146. Hall SJ, Mutchnik SE, Yang G, Timme TL, Nasu Y, Bangma CH, Woo SL, Shaker M, Thompson TC. Cooperative therapeutic effects of androgen ablation and adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy in experimental prostate cancer. Cancer Gene Ther 6(1):54-63, Jan-Feb, 1/1999. PMID: 10078964.
147. Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol 161(1):182-7, 1/1999. PMID: 10037394.
148. Thompson TC, Timme TL, Li L, Goltsov A and Yang G. A complex and provocative therapeutic target in prostate cancer and potentially other maliganancies. Emerging Therapeutic Targets 3:337-347, 1999.
149. Thompson TC. In situ gene therapy for prostate cancer. Oncol Res 11(1):1-8, 1999. PMID: 10451026.
150. Sehgal I, Thompson TC. Neuropeptides induce Mr 92,000 type IV collagenase (matrix metalloprotease-9) activity in human prostate cancer cell lines. Cancer Res 58(19):4288-91, 10/1/1998. PMID: 9766654.
151. Nasu Y, Timme TL, Yang G, Bangma CH, Li L, Ren C, Park SH, DeLeon M, Wang J, Thompson TC. Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells. Nat Med 4(9):1062-4, 9/1998. PMID: 9734401.
152. Yang G, Truong LD, Timme TL, Ren C, Wheeler TM, Park SH, Nasu Y, Bangma CH, Kattan MW, Scardino PT, Thompson TC. Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res 4(8):1873-80, 8/1998. PMID: 9717814.
153. Hampel OZ, Kattan MW, Yang G, Haidacher SJ, Saleh GY, Thompson TC, Wheeler TM, Marcelli M. Quantitative immunohistochemical analysis of insulin-like growth factor binding protein-3 in human prostatic adenocarcinoma: a prognostic study. J Urol 159(6):2220-5, 6/1998. PMID: 9598573.
154. Ren C, Yang G, Timme TL, Wheeler TM, Thompson TC. Reduced lysyl oxidase messenger RNA levels in experimental and human prostate cancer. Cancer Res 58(6):1285-90, 3/15/1998. PMID: 9515817.
155. Timme TL, Hall SJ, Barrios R, Woo SL, Aguilar-Cordova E, Thompson TC. Local inflammatory response and vector spread after direct intraprostatic injection of a recombinant adenovirus containing the herpes simplex virus thymidine kinase gene and ganciclovir therapy in mice. Cancer Gene Ther 5(2):74-82, Mar-Apr, 3/1998. PMID: 9570298.
156. Sehgal G, Hua J, Bernhard EJ, Sehgal I, Thompson TC, Muschel RJ. Requirement for matrix metalloproteinase-9 (gelatinase B) expression in metastasis by murine prostate carcinoma. Am J Pathol 152(2):591-6, 2/1998. PMID: 9466586.
157. Stapleton AM, Zbell P, Kattan MW, Yang G, Wheeler TM, Scardino PT, Thompson TC. Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery. Cancer 82(1):168-75, 1/1/1998. PMID: 9428494.
158. Thompson TC. Metastasis-related genes in prostate cancer: the role of caveolin-1. Cancer Metastasis Rev 17(4):439-42, 1999, 1998. PMID: 10453288.
159. Yang G, Timme TL, Park SH, Thompson TC. Transforming growth factor beta 1 transduced mouse prostate reconstitutions: I. Induction of neuronal phenotypes. Prostate 33(3):151-6, 11/1/1997. PMID: 9365541.
160. Yang G, Timme TL, Park SH, Wu X, Wyllie MG, Thompson TC. Transforming growth factor beta 1 transduced mouse prostate reconstitutions: II. Induction of apoptosis by doxazosin. Prostate 33(3):157-63, 11/1/1997. PMID: 9365542.
161. Hall SJ, Thompson TC. Spontaneous but not experimental metastatic activities differentiate primary tumor-derived vs metastasis-derived mouse prostate cancer cell lines. Clin Exp Metastasis 15(6):630-8, 11/1997. PMID: 9344047.
162. Stapleton AM, Timme TL, Gousse AE, Li QF, Tobon AA, Kattan MW, Slawin KM, Wheeler TM, Scardino PT, Thompson TC. Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases. Clin Cancer Res 3(8):1389-97, 8/1997. PMID: 9815823.
163. Hall SJ, Mutchnik SE, Chen SH, Woo SL, Thompson TC. Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer. Int J Cancer 70(2):183-7, 1/17/1997. PMID: 9009158.
164. Bosland MC, Chung LWK, Greenberg NM, Ho S-M, Isaacs JT, Lane K, Peehl DM, Thompson TC, van Steenbrugge GJ and van Weerden WM. Recent advances in the development of animal and cell culture models for prostate cancer research: A minireview. Urol Oncol 2:99-128, 1997.
165. Yang G, Wheeler TM, Kattan MW, Scardino PT, Thompson TC. Perineural invasion of prostate carcinoma cells is associated with reduced apoptotic index. Cancer 78(6):1267-71, 9/15/1996. PMID: 8826950.
166. Stapleton AM, Williams RH, Timme TL, Yang G, Truong LD, Thompson TC. Human cytomegalovirus is not implicated in benign prostatic hyperplasia: a study using immunohistochemistry and the polymerase chain reaction. J Urol 156(2 Pt 1):542-5, 8/1996. PMID: 8683733.
167. Sehgal I, Baley PA, Thompson TC. TGF-β1 stimulates contrasting responses in metastatic versus primary mouse prostate cancer-derived cell lines in vitro. Cancer Res 56(14):3359-65, 7/1996. PMID: 8764134.
168. Williams RH, Stapleton AM, Yang G, Truong LD, Rogers E, Timme TL, Wheeler TM, Scardino PT, Thompson TC. Reduced expression of TGF-β receptor type II in human prostate cancer: an immunohistochemical analysis. Clin Cancer Res 2(4):635-40, 4/1996. PMID: 9816213.
169. Timme TL, Yang G, Rogers E, Kadmon D, Morganstern JP, Park SH, Thompson TC. Retroviral transduction of transforming growth factor-beta1 induces pleiotropic benign prostatic growth abnormalities in mouse prostate reconstitutions. Lab Invest 74(4):747-60, 4/1996. PMID: 8606485.
170. Eastham JA, Chen SH, Sehgal I, Yang G, Timme TL, Hall SJ, Woo SL, Thompson TC. Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models. Hum Gene Ther 7(4):515-23, 3/1/1996. PMID: 8800746.
171. Yang G, Stapleton AM, Wheeler TM, Truong LD, Timme TL, Scardino PT, Thompson TC. Clustered p53 immunostaining: a novel pattern associated with prostate cancer progression. Clin Cancer Res 2(2):399-401, 2/1996. PMID: 9816183.
172. Todd D, Yang G, Brown RW, Cao J, Agati VD, Thompson TC and Truong LD. Apoptosis in renal cell carcinoma: Detection by in situ end-labelling of fragmented DNA and correlation with other prognostic factors. Hum Pathol 27:1012-1017, 1996.
173. Eastham JA, Truong LD, Rogers E, Kattan M, Flanders KC, Scardino PT, Thompson TC. Transforming growth factor-beta 1: comparative immunohistochemical localization in human primary and metastatic prostate cancer. Lab Invest 73(5):628-35, 11/1995. PMID: 7474936.
174. Eastham JA, Stapleton AM, Gousse AE, Timme TL, Yang G, Slawin KM, Wheeler TM, Scardino PT, Thompson TC. Association of p53 mutations with metastatic prostate cancer. Clin Cancer Res 1(10):1111-8, 10/1995. PMID: 9815901.
175. Baley PA, Yoshida K, Qian W, Sehgal I, Thompson TC. Progression to androgen insensitivity in a novel in vitro mouse model for prostate cancer. J Steroid Biochem Mol Biol 52(5):403-13, 5/1995. PMID: 7538321.
176. Thompson TC, Park SH, Timme TL, Ren C, Eastham JA, Donehower LA, Bradley A, Kadmon D, Yang G. Loss of p53 function leads to metastasis in ras+myc-initiated mouse prostate cancer. Oncogene 10(5):869-79, 3/2/1995. PMID: 7534899.
177. Timme TL, Truong LD, Slawin KM, Kadmon D, Park SH, Thompson TC. Mesenchymal-epithelial interactions and transforming growth factor-beta 1 expression during normal and abnormal prostatic growth. Microsc Res Tech 30(4):333-41, 3/1/1995. PMID: 7541677.
178. Greene DR, Taylor SR, Aihara M, Yoshida K, Egawa S, Park SH, Timme TL, Yang G, Scardino PT, Thompson TC. DNA ploidy and clonal selection in ras + myc-induced mouse prostate cancer. Int J Cancer 60(3):395-9, 1/27/1995. PMID: 7829250.
179. Aihara M, Scardino PT, Truong LD, Wheeler TM, Goad JR, Yang G, Thompson TC. The frequency of apoptosis correlates with the prognosis of Gleason Grade 3 adenocarcinoma of the prostate. Cancer 75(2):522-9, 1/15/1995. PMID: 7529128.
180. Donehower LA, Harvey M, vogel H, McArthur MJ, Montgomery Jr CA, park SH, Thompson TC, Ford RJ and Bradley A. Effects of genetic background of tumorigenesis in p53-deficient mice. Mol Carcinog 14:16-22, 1995.
181. Eastham JA, Hall SJ, Sehgal I, Wang J, Connel-Crowley L, Elledge SJ, Zhang W-W, Harper, JW and Thompson TC. In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res 55:5151-5155, 1995.
182. Thompson TC, Timme TL, Park SH, Ren C, Baley PA, Eastham JA, Sehgal I, Yang G and Kadmon D. Tissue and cell-cell interactions in prostate cancer progression. Cancer 75(Suppl):1885-1891, 1995.
183. Timme TL, Yang G, Truong LD, Kadmon D, Park SH, Thompson TC. Transforming growth factor-beta localization during mouse prostate morphogenesis and in prostatic growth abnormalities. World J Urol 13(6):324-8, 1995. PMID: 9116750.
184. Ohori M, Goad JR, Wheeler TM, Eastham JA, Thompson TC, Scardino PT. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol 152(5 Pt 2):1843-9, 11/1994. PMID: 7523732.
185. Timme TL, Thompson TC. Rapid allelotype analysis of p53 knockout mice. Biotechniques 17(3):460, 462-3, 9/1994. PMID: 7818898.
186. Aihara M, Truong LD, Dunn JK, Wheeler TM, Scardino PT, Thompson TC. Frequency of apoptotic bodies positively correlates with Gleason grade in prostate cancer. Hum Pathol 25(8):797-801, 8/1994. PMID: 7520020.
187. Greene DR, Rogers E, Wessels EC, Wheeler TM, Taylor SR, Santucci RA, Thompson TC, Scardino PT. Some small prostate cancers are nondiploid by nuclear image analysis: correlation of deoxyribonucleic acid ploidy status and pathological features. J Urol 151(5):1301-7, 5/1994. PMID: 8158775.
188. Timme TL, Truong LD, Merz VW, Krebs T, Kadmon D, Flanders KC, Park SH, Thompson TC. Mesenchymal-epithelial interactions and transforming growth factor-beta expression during mouse prostate morphogenesis. Endocrinology 134(3):1039-45, 3/1994. PMID: 8119140.
189. Wheeler TM, Rogers E, Aihara M, Scardino PT, Thompson TC. Apoptotic index as a biomarker in prostatic intraepithelial neoplasia (PIN) and prostate cancer. J Cell Biochem Suppl 19:202-7, 1994. PMID: 7823593.
190. Slawin K, Kadmon D, Park SH, Scardino PT, Anzano M, Sporn MB, Thompson TC. Dietary fenretinide, a synthetic retinoid, decreases the tumor incidence and the tumor mass of ras+myc-induced carcinomas in the mouse prostate reconstitution model system. Cancer Res 53(19):4461-5, 10/1/1993. PMID: 8402613.
191. Thompson TC, Truong LD, Timme TL, Kadmon D, McCune BK, Flanders KC, Scardino PT, Park SH. Transgenic models for the study of prostate cancer. Cancer 71(3 Suppl):1165-71, 2/1/1993. PMID: 8428340.
192. Truong LD, Kadmon D, McCune BK, Flanders KC, Scardino PT, Thompson TC. Association of transforming growth factor-beta 1 with prostate cancer: an immunohistochemical study. Hum Pathol 24(1):4-9, 1/1993. PMID: 7678092.
193. Thompson TC, Timme TL, Kadmon D, Park SH, Egawa S, Yoshida K. Genetic predisposition and mesenchymal-epithelial interactions in ras+myc-induced carcinogenesis in reconstituted mouse prostate. Mol Carcinog 7(3):165-79, 1993. PMID: 8489712.
194. Thompson TC, Egawa S, Kadmon D, Miller GJ, Timme TL, Scardino PT, Park SH. Androgen sensitivity and gene expression in ras + myc-induced mouse prostate carcinomas. J Steroid Biochem Mol Biol 43(1-3):79-85, 9/1992. PMID: 1525069.
195. Lu X, Park SH, Thompson TC, Lane DP. Ras-induced hyperplasia occurs with mutation of p53, but activated ras and myc together can induce carcinoma without p53 mutation. Cell 70(1):153-61, 7/10/1992. PMID: 1623518.
196. Egawa S, Kadmon D, Miller GJ, Scardino PT, Thompson TC. Alterations in mRNA levels for growth-related genes after transplantation into castrated hosts in oncogene-induced clonal mouse prostate carcinoma. Mol Carcinog 5(1):52-61, 1992. PMID: 1543541.
197. Thompson TC, Truong LD, Timme TL, Kadmon D, McCune BK, Flanders KC, Scardino PT, Park SH. Transforming growth factor-β1 as a biomarker for prostate cancer. J Cell Biochem Suppl 16H:54-61, 1992. PMID: 1289674.
198. Kadmon D, Thompson TC, Lynch GR, Scardino PT. Elevated plasma chromogranin-A concentrations in prostatic carcinoma. J Urol 146(2):358-61, 8/1991. PMID: 1856931.
199. Merz VW, Miller GJ, Krebs T, Timme TL, Kadmon D, Park SH, Egawa S, Scardino PT, Thompson TC. Elevated transforming growth factor-β1 and β3 mRNA levels are associated with ras + myc-induced carcinomas in reconstituted mouse prostate: evidence for a paracrine role during progression. Mol Endocrinol 5(4):503-13, 4/1991. PMID: 1922083.
200. Thompson TC, Kadmon D, Timme TL, Merz VW, Egawa S, Krebs T, Scardino PT, Park SH. Experimental oncogene induced prostate cancer. Cancer Surv 11:55-71, 1991. PMID: 1726789.
201. Thompson TC. Growth factors and oncogenes in prostate cancer. Cancer Cells 2(11):345-54, 11/1990. PMID: 2282250.
202. Thompson TC, Southgate J, Kitchener G, Land H. Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ. Cell 56(6):917-30, 3/1989. PMID: 2538247.
203. Compere SJ, Baldacci P, Sharpe AH, Thompson TC, Land H and Jaenisch R. The ras and myc oncogenes cooperate in tumor induction in many tissues when introduced into midgestation mouse embryos by retroviral vectors. Proc Natl Acad Sci USA 86:2224-2228, 1989.
204. Mills JS, Needham M, Thompson TC, Parker MG. Androgen-regulated expression of secretory protein synthesis in mouse ventral prostate. Mol Cell Endocrinol 53(1-2):111-8, 9/1987. PMID: 3666286.
205. Thompson TC, Zhau HY, Chung LW. Catecholamines are involved in the growth and expression of prostatic binding protein by rat ventral prostatic tissues. Prog Clin Biol Res 239:239-48, 1987. PMID: 2821548.
206. Thompson TC, Cunha GR, Shannon JM, Chung LW. Androgen-induced biochemical responses in epithelium lacking androgen receptors: characterization of androgen receptors in the mesenchymal derivative of urogenital sinus. J Steroid Biochem 25(5A):627-34, 11/1986. PMID: 3795942.
207. Thompson TC, Chung LW. Regulation of overgrowth and expression of prostatic binding protein in rat chimeric prostate gland. Endocrinology 118(6):2437-44, 6/1986. PMID: 2422020.
208. Thompson TC and Chung LWK. Evidence for a urogenital sinus-derived growth factor(s). Ann NY Acad Sci 438:582-5, 1985.
209. Chung LWK, Matsuura J, Rocco AK, Thompson TC, Miller GJ and Runner MN. Tissue interactions and prostatic growth. Ann NY Acad Sci 438:582-585, 1985.
210. Thompson TC, Chung LW. Extraction of nuclear androgen receptors by sodium molybdate from normal rat prostates and prostatic tumors. Cancer Res 44(3):1019-26, 3/1984. PMID: 6692389.
211. Chung LW, Matsuura J, Rocco AK, Thompson TC, Miller GJ, Runner MN. A new mouse model for prostatic hyperplasia: induction of adult prostatic overgrowth by fetal urogenital sinus implants. Prog Clin Biol Res 145:291-306, 1984. PMID: 6201880.
212. Thompson TC, Chung LW. Evidence for a soluble fetal urogenital sinus-derived growth factor(s). Ann N Y Acad Sci 438:582-5, 1984. PMID: 6085457.
213. Neubauer BL, Chung LW, McCormick KA, Taguchi O, Thompson TC, Cunha GR. Epithelial-mesenchymal interactions in prostatic development. II. Biochemical observations of prostatic induction by urogenital sinus mesenchyme in epithelium of the adult rodent urinary bladder. J Cell Biol 96(6):1671-6, 6/1983. PMID: 6853598.
214. Chung LW, Matsuura J, Thompson TC, Chao RC. A new approach to regulation of prostatic growth: interactions between embryonic urogenital sinuses and adult prostate in situ. Proc West Pharmacol Soc 25:141-5, 1982. PMID: 6889738.
215. Chung LW, Thompson TC, Breitweiser K. Sensitive biochemical methods to distinguish hormone dependent and independent Dunning tumors of prostatic origin. Proc West Pharmacol Soc 24:305-10, 1981. PMID: 6265951.
216. Karanika S, Karantanos T, Wang J, Li L, Park S, Yang G, Song JH, Maity SN, Manyam GC, Broom B, Aparicio AM, Gallick G, Troncoso P, Corn PG1, Navone NM, Thompson TC. Targeting DNA damage response in prostate cancer through inhibition of androgen. Cell Reports. Submitted.

Editorials

1. Kadmon D and Thompson TC. Mechanisms of developing androgen independence in carcinoma of the prostate. Prospectives: Internal Prostate Health Council Newsletter, 2007.
2. Thompson TC. Cancer Biology and the Mutant Mouse: New Methods, New Models, New Insights (Meeting News). Investigational Drugs (ID) Weekly Highlights, Current Drugs Ltd, London, UK:26-29, 3/1999.
3. Thompson TC, Kadmon D, Timme TL, Egawa S, Krebs T, Merz VW, Park SH, Ripoll E, Scardino PT. Experimental, oncogene-induced prostate cancer. Baylor Urologic Update, 6/1991.
4. Tindall DJ, Thompson TC, Buttyan R. Molecular biology: understanding methods and applications. AUA Annual Meeting, Text for Postgraduate Course, 1990.
5. Thompson TC. Uncoupling of growth and differentiation in rat ventral prostate: Involvement of 5-hydroxytryptamine and norepinephrine, 1985.
Other Articles
1. Thompson TC, Timme TL and Sehgal I. The role of p53 in prostate cancer progression. General Motors Cancer Research Foundation Accomplishments in Cancer Research 1996:280-288, 1997.
2. Kadmon D and Thompson TC. Mechanisms of developing androgen independence in carcinoma of the prostate. PROspectives: Contemporary Issues in Managing Prostatic Disease 5:1-3, 1995.
3. Thompson TC, Timme TL, Egawa S, Yoshida K, Park SH, Baley PA, Slawin K and Kadmon D. Mesenchymal-epithelial interactions during prostate carcinogenesis. Fundamental Approaches to the Diagnosis and Treatment of Prostate Cancer and BPH: Proceedings of the Fifth Tokyo Symposium:105-108, 1994.
4. Thompson TC, Slawin K, Kadmon D, Park SH, Timme TL, Yoshida K, Ren C, Truong LD, Scardino PT and Eastham JA. Molecular pathways in prostate carcinogenesis. Fundamental Approaches to the Diagnosis and Treatment of Prostate Cancer and BPH: Proceedings of the Fifth Tokyo Symposium:145-149, 1994.
5. Thompson TC, Timme TL, Egawa S, Park SH, Kadmon D, Yoshida K, Scardino PT and Mottaz A. Genetic differences in susceptibility to ras+myc-induced carcinogenesis in reconstituted mouse prostate involves mesenchymal-epithelial interactions. Progress in Endocrinology: Proceedings of Ninth International Congress on Endocrinology, 1993.
6. Chung LWK, Thompson TC, Chao HY, Bell C and Ruth JA. Catecholamines are involved in stromal-epithelial interactions in rat ventral prostate gland. Second NIADDK Symposium on Benign Prostatic Hyperplasia, 5/1985.
7. Chung LWK, Matsuura J, Rocco AK, Thompson TC, Miller GJ, and Runner MN. A new mouse model for prostatic hyperplasia: induction of adult prostatic overgrowth by fetal urogenital sinus implants. New Approaches to The Study of Benign Prostatic Hyperplasia. BPH Workshop, 1984.

Abstracts

1. Basourakos S, Davis J, Chapin BF, Ward J, Pettaway C, Pisters L, Achim M, Wang X, Choi S, Kuban DA, Troncoso P, Logothetis C, Thompson TC, Kim J. Plasma caveolin-1 predicts disease reclassification in men with early stage prostate cancer in active surveillance. 2016 ASCO Annual Meeting, Chicago, IL, 6/2016.
2. Karantanos T, Song KD, Wang J, Masato D, Yang G, Park S, Wenling Z, Thompson T. Caveolin-1 activates lipid synthesis and promotes prostate cancer growth following androgen deprivation. 20th Annual PCF Scientific Retreat, National Harbor, MD, 10/2013.
3. Karantanos T, Hirayama T, Wang J, Goltsov AA, Park S, Thompson TC. Caveolin-1 monoclonal antibody and 3BrPA combined therapy targeting aerobic glycolysis in prostate cancer. Keystone Symposia, 3/2013.
4. Thompson TC, Li L, Yang G, Ren C, Chang W, Hirayama T, Kim SM, Lee JS, Troncoso P, Park S. c-Myb and its targets as drivers in prostate cancer progression. The 6th Severence- MD Anderson Cancer Center Joint Symposium - "Personalized Cancer Therapy and Prevention.", 10/2012.
5. Elliott, MH, Dozmorov M, Li X, Iqbal H, McClellan M, Wren JD, Cao G, Thompson TC, Ueffing M, Jauck SM. Insights into caveolin-1 function: quantitative proteomic analysis of a novel retina-specific knockout mouse model. ARVO 2012, Translational Research: Seeing the Possibilities, 12/2011.
6. Thompson TC, Li L, Ren C, Yang G, Goltsov A, Abdel-Fattah E. Glioma pathogenesis-related protein 1, a tumor suppressor that stimulates oncoprotein destruction. 7th Annual National Symposium on Prostate Cancer, Clark Atlanta University, 5/2011.
7. Thompson TC, Li L, Ren C, Yang G, Goltsov A, Abdel-Fattah E. GLIPR1 suppresses prostate cancer through targeted oncoprotein destruction. The 5th Severence-MD Anderson Cancer Center Joint Symposium- "Personalized Cancer Therapy and Prevention", 5/2011.
8. Carthon B, Tahir S, Yang G, Wan X, Yang J, Tanimoto R, Kurosaka S, Park S, Goltsov A, Traoncoso P, Araujo J, Wen S, Gallick G, Navone N, Logothetis C, Thompson T. Caveolin-1 as a biomarker of osteoblast activation and Src family kinase/Abl inhibition in castrate-resistant prostate cancer. United States Department of Defense-Innovative Minds in Prostate Cancer Today (DOD-IMPACT) Conference, March 9-12, 2011, 3/2011.
9. Thompson TC, Li L, Ren C, Yang G, Goltsov A, Abdelfattah E-M. Glioma pathogenesis-relate protein 1, a tumor suppressor that stimulates oncoprotein destruction. United States Departmetn of Defense-Innovative Minds in Prostate CAncer Today (DOD-IMPACT) Conference, March 9-12, 2011, 3/2011.
10. Carthon B, Tahir S, Araujo J, Wen S, Gallick G, Logothetis C,Thompson T. Caveolin-1 as a biomarker of Src kinase inhibition in castration resistant prostate cancer. 2011 ASCO Genitourinary Cancers Symposium, Feb 17-19, 2011, 2/2011.
11. Carthon B, Tahir S, Araujo J, Wen S, Gallick G, Logothetis C, Thompson T. Serum Caveolin-1 as a biomarker of Src kinase inhibition in castration resistant prostate cancer. Innovations in Cancer Research and Prevention and Research Conference, Nov 17-19, 2010, 11/2010.
12. Tahir SA, Kurosaka S, Tanimoto R, Goltsov A, Park SH, Thompson TC. Caveolin-1 as a biomarker of drug response and therapeutic target in association with tyrosine kinase inhibitor treatment in prostate cancer models. AACR Translational Cancer Medicine 2010, Amsterdam, The Netherlands, 3/2010.
13. Kadmon D, Sonpavde G, Jain RK, Ayala GE, Ittmann MM, Kurosaka S, Edamura K, Tabata KI, Miles BJ , Thompson TC. GLIPR1/RTVP-1 tumor suppressor gene expressed by adenovirus vector as neoadjuvant intraprostatic injection for localized high-risk prostate cancer preceding prostatectomy. 2010 ASCO Genitourinary Cancer Symposium, San Francisco, CA (#59), 3/2010.
14. Kadmon D, Sonpavde G, Jain RK, Ayala GE, Ittmann MM, Kurosaka S, Edamura K, Tabata KI, Miles BJ, Thompson TC. GLIPR1/RTVP-1 tumor suppressor gene expressed by adenovirus vector as neoadjuvant intraprostatic injection for localized high-risk prostate cancer preceding prostatectomy. 2010 ASCO Annual Meeting, Chicago, IL (#51288), 2010.
15. Langeberg WJ, Tahir SA, Feng Z, Kwon EM, Ostrander EA, Thompson TC, Stanford JL. Association of Caveolin-1 and -2 Genetic Variants and Post-treatment Serum Caveolin-1 with Prostate Cancer Risk and Outcomes. 42nd Annual SER Meeting, Anaheim, California, 6/2009.
16. Tahir SA, Park SH, Thompson TC. Caveolin-1 regulates VEGF/VEGFR2 induced angiogenic signaling. AACR 100th Annual Meeting, Denver, Colorado, 4/2009.
17. Li L, Ren C, Yang G, Abdel Fattah E, Timme TL, Goltsov AA, Park SH, Thompson TC. GLIPR1 tumor suppressor activities involve suppression of specificity protein1 and its target genes c-myc. AACR 100th Annual Meeting, Denver, Colorado, 4/2009.
18. Sonpavde G, Frolov A, Macdonell V, Hayes TG, Mims MP, Ayala GE, Wheeler TM, Thompson TC, Ittman MM, Kadmon D. Bortezomib as brief neoadjuvant therapy for localized high-risk prostate cancer followed by radical prostatectomy. 2009 ASCO Annual Meeting, Orlando, Florida, 2009.
19. Ayala G, Mims MP, Wheeler TM, Tabata KI, Edamura K, Sayeeduddin M, Ren CZ, Gee A, Brenner MB, MacDonnell V, Miles BJ, Thompson TC and Kadmon D. Biological responses following intratumoral injection of AdGLIPR1: preliminary results from a Phase I/II neoadjuvant gene therapy trial. 15th Annual SPORE Investigator’s Workshop, Baltimore, Maryland, 7/2007.
20. Miyahara Y, Kiniwa Y, Wang HY, Pen W, Peng G, Wheeler TM, Thompson TC and Wang R-F. Critical role of different subsets of regulatory T cells in suppressing immune responses to prostate cancer. 15th Annual SPORE Investigator’s Workshop, Baltimore, Maryland, 7/2007.
21. Ayala G, Li R, Wheeler TM, Thompson TC and Rowley D. Epigenetic based nomograms in prostate cancer. 15th Annual SPORE Investigator’s Workshop, Baltimore, Marlyand, 7/2007.
22. Miles BJ, Yang G, Addai J, Wheeler TM, Frolov A, Kadmon D and Thompson TC. Correlative evidence that prostate cancer cell-derived caveolin-1 mediates angiogenesis. American Society of Clinical Oncology Annual Meeting, Chicago, Illinois, 6/2007.
23. Brown K, Thompson TC, Ren CZ, Rahmani M, and Younes M. Decreased GLIPR1 expression in esophageal adenocarcinoma. American Gastroenterology Association, Digestive Disease Week, Washington, DC, 5/2007.
24. Tabata K, Watanabe M, Edamura K, Yang G, Wang J, Abdel Fattah EM, Kadmon D and Thompson TC. Macrophages transduced with an adenovial vector expressing Glipr1 suppress tumor growth and metastasis in a preclinical metastatic prostate cancer model. 10th Annual American Society for Gene Therapy meeting, Seattle, Washington, 5/2007.
25. Tahir SA, Yang G, Goltsov A, Watanabe M, Tabata K and Thompson TC. Caveolin-1 uptake by endothelial cells promotes angiogenic activities and is associated with prostate cancer progression. 4th Annual Cancer Center Symposium, Houston, Texas, 11/2006.
26. Goltsov AA, Ren CZ, Yang G, Wang J, Li L, Timme TL and Thompson TC. Expression and functional analysis of PERP in mouse and human prostate cancer. 4th Annual Cancer Center Symposium, Houston, Texas, 11/2006.
27. Tabata K, Watanabe M, Edamura K, Wang J, Abdel Fattah, M, Yang G, Floryk D, Kadmon D and Thompson TC. Therapeutic activities of IL-12 gene-modified macrophages embedded in gelatin matrix hemostatic sealant (FLOSEAL) in a mouse model of residual prostate cancer. Center for Cell and Gene Therapy Conference, Galveston, Texas, 11/2006.
28. Kadmon D, Tabata K, Watanabe M, Naruishi K, Satoh T, Tian WT, Wang HY, Abdel Fattah M, Yang G and Thompson TC. Gene-modified macrophage therapy for recurrent prostate cancer. 14th Annual SPORE Investigator’s Meeting, Baltimore, Maryland, 7/2006.
29. Tabata K, Watanabe M, Satoh T, Tian WT, Wang HY, Abdel Fattah M, Yang G, Floryk D, Kadmon D and Thompson TC. Therapeutic activities of IL-12 gene-modified macrophages embedded in gelatin matrix hemostatic sealant (FloSeal) in a mouse model of residual prostate cancer. American Society of Gene Therapy 9th Annual Meeting, Baltimore, Maryland, 6/2006.
30. Tabata KI, Watanabe M, Naruishi K, Satoh T, Tian WT, Wang HY, Abdelfattah E-M, Yang G, Thompson TC, Kadmon D. Therapeutic activities of IL-12 gene-modified macrophages embedded in florseal in a mouse model of residual prostate cancer. American Urological Association meeting, Atlanta, Georgia, 5/2006.
31. Tahir SA, Yang G, Goltsov A, Watanabe M, Tabata K, and Thompson TC. Caveolin-1 uptake by endothelial cells promotes angiogenic activities and is associated with prostate cancer progression. American Association for Cancer Research, 97th Annual Meeting, Washington DC, 4/2006.
32. Goltsov A, Ren CZ, Yang G, Wang J, Li L, Timme TL, and Thompson TC. . Expression and functional analysis of PERP in mouse and human prostate cancer. American Association for Cancer Research, 97th Annual Meeting, Washington DC, 4/2006.
33. Thompson TC, Li L, Ren C, Ren CZ, Abdelfattah E-M, Goltsov A, Yang G, Wang J, Troung LD, Ittmann M, Wheeler TM, Ayala G, Kadmon D. Identification, characterization and functional analysis of RTVP-1/GLIPR-like genes – a novel p53 target gene cluster with tumor suppressor functions. 2006 Prostate Cancer Inter-SPORE Meeting, Houston, Texas, 2/2006.
34. Tabata KI, Watanabe M, Naruishi K, Satoh T, Tian WT, Wang HY, Abdelfattah E-M, Yang G, Thompson TC, Kadmon D. Therapeutic activities of IL-12 gene-modified macrophages embedded in florseal in a mouse model of residual prostate cancer. 2006 Prostate Cancer Inter-SPORE Meeting, Houston, Texas, 2/2006.
35. Thompson TC, Kadmon D, Li L, Ren CZ, Ren CH, Tahir S, Ayala G, Wheeler TM, Mims MP, Hayes T and Lynch GR. Development of RTVP-1 protein therapy for prostate cancer. 1st Place Award, 3rd Annual Cancer Center Symposium, Houston, TX, 11/2005.
36. Tabata K, Watanabe M, Naruishi K, Satoh T, Tian WT, Wang H, Abdel Fattah EM, Yang G, Kadmon K, Thompson TC. Therapeutic activities of IL-12 gene-modified macrophages embedded in Floseal in a mouse model of residual prostate cancer. 2005 Center for Cell and Gene Therapy Conference, Galveston, Texas, 11/2005.
37. Kadmon D, Tahir S, Li L, Ayala G, Wheeler TM, Frolov A, Thompson TC. The role of secreted caveolin-1 in prostate cancer progression. 12th Annual Prostate Cancer Foundation Scientific Retreat, Pheonix, Arizona, 9/2005.
38. Thompson TC, Kadmon D, Li L, Ren CZ, Ren C, Tahir S, Ayala G, Wheeler TM, Mims MP, Hayes T, Lynch GR. Development of RTVP-1 protein therapy for prostate cancer. 13th Annual SPORE Investigators Workshop, Washington, DC, 7/2005.
39. Kadmon D, Tahir S, Li L, Ayala G, Wheeler TM, Frolov A, Thompson TC. The role of secreted caveolin-1 in prostate cancer progression. 13th Annual SPORE Investigators Workshop, Washington, DC, 7/2005.
40. Fujita T, Timme TL, Naruishi K, Kusaka N, Zhu JX, Yang G, Goltsov A, Ren C, Ren CZ, Vlachaki MT, Teh BS, Butler EB, Thompson TC. Cooperative effects of adenoviral vector-mediated interleukin 12 gene therapy and radiotherapy in a preclinical model of metastatic prostate cancer. American Society for Gene Therapy, St. Louis, Missouri, 6/2005.
41. Wang HY, Abdelfattah M, Tahir SA, Yang G, Goltsov A, Tian WT, Ren CZ, Ren C, Timme TL, Thompson TC. RTVP-1 protein stimulates markers of maturation in mouse and human dendritic cells. American Society for Gene Therapy, St. Louis, Missouri, 6/2005.
42. Fujita F, Timme TL, Naruishi K, Kusaka N, Zhu JX, Yang G, Goltsov A, Ren C, Ren CZ, Vlachaki MT, Teh BS, Butler EB, Thompson TC. Cooperative effects of adenoviral-mediated interleukin 12 gene therapy and radiotherapy in a preclinical model of metastatic prostate cancer. American Urological Association Meeting, San Antonio, Texas, 5/2005.
43. Fujita F, Teh BS, Timme TL, Mai WY, Satoh T, Kusaka N, Naruishi K, Abdel Fattah E, Aguilar-Cordova E, Butler EB, Thompson TC. Sustained long-term immune responses following combination in situ gene therapy, radiotherapy and hormonal therapy for prostate cancer. American Urological Association meeting, San Antonio, Texas, 5/2005.
44. Koh M, Sanabria G, Ittmann M, Thompson TC, Leach F. F-Box gene expression as potential biomarkers for targeted therapy in prostate cancer. Inter-Prostate SPORE meeting, Houston, Texas, 1/2005.
45. Kadmon D, Tahir SA, Li L, Ayala G, Wheeler TM, Frolov A, Thompson TC. The role of secreted caveolin-1 in prostate cancer progression. Inter-Prostate SPORE Meeting, Houston, Texas, 1/2005.
46. Fujita T, Timme TL, Naruishi K, Kusaka N, Zhu J, Yang G, Goltsov A, Vlachaki M, Teh BS, Butler EB, Thompson TC. Cooperative effects of adenoviral vector-mediated interleukin 12 gene therapy and radiotherapy in a preclinical model of metastatic prostate cancer. 2nd Annual Cancer Center Symposium, Houston, Texas, 10/2004.
47. Wang H, Yang G, Timme TL, Fujita T, Naruishi K, Ji X, Brenner M, Kadmon D, Thompson TC. IL-12 gene modified bone marrow stem cell therapy in a mouse model of metastatic prostate cancer. 2nd Annual Cancer Center Symposium, Houston, Texas, 10/2004.
48. Wang H, Yang G, Timme TL, Fujita T, Naruishi K, Ji X, Brenner MK, Kadmon D, Thompson TC. IL-12 gene modified bone marrow stem cell therapy in a mouse model of metastatic prostate cancer. Prostate Cancer Foundation 11th Annual Scientific Retreat, Lake Tahoe, Nevada, 10/2004.
49. Teh BS, Amato RJ, Fujita T, Timme TL, Miles BJ, Ayala G, Wheeler TM, Kadmon D, Butler EB, Thompson TC. Combination adenoviral vector-mediated interleukin 12 gene therapy plus radiotherapy for prostate cancer #182. 12th SPORE Investigators' Workshop, Baltimore, Maryland, 7/2004.
50. Wang H, Yang G, Timme TL, Fujita T, Naruishi K, Ji X, Tian W-H, Brenner MK, Kadmon D, Thompson TC. IL-12-transduced bone marrow cells home to bone and generate anti-metastatic activities in a mouse prostate cancer model #183. 12th SPORE Investigators' Workshop, Baltimore, Maryland, 7/2004.
51. Ayala G, Li R, Frolov A, Ittman M, Dai H, Mohammed S, Scardino P, Thompson TC, Wheeler TM, Etzioni R. Increasing the predictive ability of clinico-pathologic markers for prostate cancer using biomarkers derived from high-throughput tissue microarray studies in a large retrospective cohort: A stratification strategy #125. 12th SPORE Investigators' Workshop, Baltimore, Maryland, 7/2004.
52. Wang HY, Yang G, Timme TL, Fujita T, Naruishi K, Ji X, Brenner M, Kadmon D, Thompson TC. IL-12 transduced bone marrow cells home to bone and generate anti-metastatic activities in a mouse prostate cancer model. 7th Annual American Society of Gene Therapy meeting, Minneapolis, Minnesota, 6/2004.
53. Satoh T, Teh BS, Timme TL, Mai W-Y, Vlachaki MT, Kusaka N, Fujita T, Abd-El-Fattah E-M, Gdor Y, Kadmon D, Butler EB Thompson TC. Enhanced systemic T-cell responses following combination in situ gene therapy + radiotherapy or hormonal therapy for prostate cancer. American Urological Association Annual Meeting, San Francisco, California, 5/2004.
54. Lai HH, Boone TB, Yang G, Smith CP, Kiss S, Thompson TC, Somogyi GT. Loss of caveolin-1 expression is associated with bladder hypocontraction and disruption of muscarinic cholinergic activity of the bladder via pre- and post-junctional mechanisms. American Urological Association Annual Meeting, San Francisco, California, 5/2004.
55. Teh BS, Ayala G, Wheeler T, Miles B, Kadmon D, Amato R, Butler EB, Timme TL and Thompson TC. Combination immuno-gene therapy and irradiation for prostate cancer: achieving maximal tumor control through anti-tumor immunity. InterProstate SPORE Meeting, Chicago, Illinois, 1/2004.
56. Kadmon D, Tahir SA, Timme TL, Li L, Abd-El-Fattah E-M, Frolov A, Ayala G, Wheeler TM and Thompson TC. Serum caveolin-1 as a biomarker for prostate cancer. InterProstate SPORE Meeting, Chicago, Illinois, 1/2004.
57. Naruishi K, Fujita T, Kusaka N, Goltsov AA, Ji X, Men T, Timme TL, Thompson TC. Adenoviral vector-mediated mRTVP-1 gene modified cell-based vaccination for prostate cancer. 1st Annual Cancer Center Retreat & Symposium, Houston, Texas, 11/2003.
58. Wang H, Yang G, Satoh T, Kusaka N, Ji X, Timme TL, Fujita T, Men T, Brenner MK, Kadmon D, Thompson TC. Antimetastatic effects of IL-12 gene-modified bone marrow cells in a mouse model of metastatic prostate cancer. 1st Annual Cancer Center Retreat & Symposium, Houston, Texas, 11/2003.
59. Li L, Ren C-H, Tahir SA, Ren C and Thompson TC. Caveolin-1 maintains activated akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. 1st Annual Cancer Center Retreat & Symposium, Houston, Texas, 11/2003.
60. Fujita T, Vlachaki MT, Zhu X, Satoh T, Naruishi K, Kusaka N, Timme TL, Teh BS, Butler EB, Thompson TC. Enhanced therapeutic effect of adenoviral vector-mediated RTVP-1 gene therapy in combination with irradiation for prostate cancer. 1st Annual Cancer Center Retreat & Symposium, Houston, Texas, 11/2003.
61. Teh BS, Ayala G, Aguilar L, Mai WY, Valchaki M, Caillouet J, Davis M, Wheeler T, Miles B, Kadmon D, Woo SY, Carpenter LS, Lu HH, Thompson TC, Aguilar-Cordova E and Butler EB. Phase I/II trial evaluating combined radiotherapy and in-situ gene-therapy with or without hormonal therapy in the treatment of prostate cancer — a report on PSA response and biopsy data. 1st Annual Cancer Center Retreat & Symposium, Houston, Texas, 11/2003.
62. Kadmon D, Amato RJ, Thompson TC and Miles. Development of RTVP-1 immuno-gene therapy for prostate cancer. 11th SPORE Investigators’ Workshop, Baltimore, Maryland, 7/2003.
63. Ayala GA, Dai H, Frolov A, Li R, Wheeler T, Ittmann M, Thompson TC and Rowley D. Paracrine interactions between prostate cancer and nerves leads to neural hyperplasia in the prostate. 11th SPORE Investigators’ Workshop, Baltimore, Maryland, 7/2003.
64. Timme TL, Salahaldin TA, Abd-El-Fatah EA, Frolov A, Richardson B, Ayala G, Wheeler TM and Thompson TC. Serum caveolin-1 as a biomarker for prostate cancer. 11th SPORE Investigators’ Workshop, Baltimore, Maryland, 7/2003.
65. Tahir SA, Ren C, Timme TL, Gdor Y, Frolov A, Hoogeveen R, Morrisett JD, Ayala G, Wheeler TM and Thompson TC. Serum caveolin-1 discriminate between BPH and prostate cancer and is a prognostic marker for prostate cancer progression. American Association for Cancer Research, Washington, DC, 7/2003.
66. Wang H, Yang G, Satoh T, Kusaka N, Ji X, Timme TL, Fujita T, Men T and Thompson TC. Antimetastatic effects of IL-12 gene-modified bone marrow cells in a mouse model of metastatic prostate cancer. American Society of Gene Therapy Annual Meeting, Boston, Massachusetts, 6/2003.
67. Satoh T, Teh BS, Timme TL, Mai W-Y, Vlachaki MT, Kusaka N, Fujita T, Abd-El-Fatah EA, Gdor Y, Kadmon D, Butler EB and Thompson TC. Enhanced systemic T-cell responses following combination in situ gene therapy + radiotherapy or hormonal therapy for prostate cancer. American Society of Gene Therapy Annual Meeting, Boston, Massachusetts, 6/2003.
68. Satoh T, Timme TL, Saika T, Ebara S, Yang G, Wang J, Ren C, Kusaka N, Mouraviev VB, Thompson TC. Adenoviral vector-mediated in situ gene therapy for prostate cancer: mRTVP-1 suppresses tumor growth and metastasis through pro-apoptotic and immunostimulatory activities. American Urological Association Annual Meeting, Chicago, Illinois, 4/2003.
69. Saika T, Kusaka N, Satoh T, Mouraviev V, Kumon H, Timme TL, Thompson TC. Adoptive transfer of splenocytes from mice treated in situ with ADIL-12 results in suppression of tumor growth and metastasis and increased survival in a model for residual tumor after neo-adjuvant in-situ gene therapy for prostate cancer. American Urological Association Annual Meeting, Chicago, Illinois, 4/2003.
70. Lai HH, Kiss S, Smith CP, Thompson TC, Boone TB, Somogyi GT. Cystometric abnormalities of caveolin-1 knockout mice: an animal model of urinary calculi formation. Society for Urodynamics and Female Urology / Specialty Society Meeting at American Urological Association Annual Meeting, Chicago, Illinois, 4/2003.
71. Wheeler TM, Li R, Yang G, Frolov A, Thompson TC, Harper W, Ayala G. GSK expression predicts biochemical recurrence in human prostate cancer after prostatectomy. American Urological Association Annual Meeting, Chicago, Illinois, 4/2003.
72. Ayala G, Li R, Yang G, Wheeler TM, Spitler J, Frolov A, Thompson TC, Harper W. High levels of P-AKT in prostate cancer and normal tissues are independent predictors of biochemical recurrence. American Urological Association Annual Meeting, Chicago, Illinois, 4/2003.
73. Cao G, Yang G, Timme TL, Saika T, Truong LD, Satoh T, Goltsov A, Park SH, Men T, Kusaka N, Tian W, Ren C, Wang H, Kadmon D, Cai WW, Chinault AC, Boone TB Bradley A, Thompson TC. Targeted inactivation of caveolin-1 impairs renal calcium reabsorption and leads to hypercalciuria and urolithiasis. American Urological Association Annual Meeting, Chicago, Illinois, 4/2003.
74. Saika T, Kusaka N, Satoh T, Mouraview VB, Kumon H, Timme TL, and Thompson TC. Adoptive transfer of splenocytes from mice treated in situ with AdlL-12 results in suppression of tumor growth and metastasis and increased survival in a model for risidual tumor after neo-adjuvant in situ gene therapy for prostate cancer. American Society of Gene Therapy 5th Annual Meeting, Boston, Massachusetts (#332), 6/2002.
75. Satoh T, Vlachaki MT, Zhu X, Kusaka N, Saika T, Timme TL, Yang G, Mouraviev VB, Wang J, Teh B, Butler B, and Thompson TC. Enhanced therapeutic effect of mRTVP-1 gene therapy in combination with irradiation for prostate cancer. American Society of Gene Therapy 5th Annual Meeting, Boston, Massachusetts (#332), 6/2002.
76. Harper W, Yang G, Wheeler T, Frolov A, Thompson TC, and Ayala GE. Elevated Skp2 protein expression in human prostate cancer is associated with reduced recurrence-free survival. American Urological Association 97th Annual Meeting, Orlando, Florida (#900), 5/2002.
77. Satoh T, Saika T, Ebara S, Kusaka N, Yang G, Wang J, Mouraviev V, Cao G, Timme TL, and Thompson TC. Macrophages transduced with adenoviral vectors to express IL-12 suppress tumor growth and metastasis in pre-clinical models of prostate cancer. American Urological Association 97th Annual Meeting, Orlando, Florida (#199), 5/2002.
78. Ayala GE, Dai H, Wheeler T, Ali N, Thompson TC, and Ittmann M. Perineural antiapopototic mechanisms – the cancer loop. American Urological Association 97th Annual Meeting, Orlando, Florida (#567), 5/2002.
79. Ayala GE, Wheeler T, Tuxhorn J, Frolov A, Wheeler M, Spitler J, Thompson TC, and Rowley D. Quantitation of intratumoral reactive stroma as a predictor of biochemical free recurrence in prostate cancer (PCA). American Urological Association 97th Annual Meeting, Orlando, Florida (#545), 5/2002.
80. Saika T, Kusaka N, Satoh T, Mouraviev VB, Yang G, Timme TL, and Thompson TC. Sub-cutaneous injection of bone marrow derived dendritic cells engineered to produce interleukin-12 induces anti-tumor activities in an orthotopic mouse prostate cancer model. American Urological Association 97th Annual Meeting, Orlando, Florida (#214), 5/2002.
81. Satoh T, Lee H-M, Pramudji CK, Timme TL, Shalev M, Godor Y, Mai W-Y, Teh B, Vlachaki MT, Saika T, Kusaka N, Ayala G, Wheeler TM, Butler EB, Miles BJ, Kadmon D, and Thompson TC. Systemic T-cell activation following in situ gene therapy in prostate cancer patients. American Urological Association 97th Annual Meeting, Orlando, Florida (#1205), 5/2002.
82. Ren C, Li L, Goltsov A, Timme TL, Tahir SA, Wang J, Garza L, Chinault CA and Thompson TC. mRTVP-1, a novel p53 target gene with pro-apoptotic activities. 93rd Annual Meeting of the Proceedings of the American Association for Cancer Research, San Francisco, California (#1637), 4/2002.
83. Goltsov AA, Ren C, Wang J, Tahir S, Li L, Timme TL, and Thompson TC. Overexpression of PERP is associated with increased motility of prostate cancer cells. 93rd Annual Meeting of the Proceedings of the American Association for Cancer Research, San Francisco, California (#5166), 4/2002.
84. Tahir SA, Gdor Y, Mouraviev V, Frolov A, Ren C, Li L, Timme TL, Morrisett JD and Thompson TC. Serum caveolin-1 as a novel biomarker for prostate cancer. 93rd Annual Meeting of the Proceedings of the American Association for Cancer Research, San Francisco, California (#826), 4/2002.
85. Thompson TC, Timme TL, Egawa S, Yoshida K, Park SH, Baley PA, Slawin K, Kadmon D. Mesenchymal-epithelial interactions during prostate carcinogenesis. Fundamental Approaches to the Diagnosis and Treatment of Prostate Cancer and BPH: Proceedings of the Fifth Tokyo Symposium:105-8, 1994.
86. Thompson TC, Slawin K, Kadmon D, Park SH, Timme TL, Yoshida K, Ren C, Truong LD, Scardino PT and Eastham JA. Molecular pathways in prostate carcinogenesis. Fundamental Approaches to the Diagnosis and Treatment of Prostate Cancer and BPH: Proceedings of the Fifth Tokyo Symposium:145-9, 1994.

Book Chapters

1. Satoh T, Timme TL, Gdor Y, Miles BJ, Amato RJ, Kadmon D, and Thompson TC. Immunogene therapy for metastatic prostate cancer. In: Cancer Metastatsis: Biology and Treatment. In Press.
2. Thompson TC, Tahir S, Li L, Watanabe M, Naruishi K, Yang G, Tabata K, Kurosaka S, Edamura K, Tanimoto R, Corn P, Kadmon D, Logothetis CJ, Troncoso P, Ren C, Goltsov A, Park S. Local and Distant Effects of Caveolin-1 on Prostate Cancer Progression. In: Caveolins in Cancer Pathogenesis, Prevention and Therapy. Springer: United Kingdom, 1-15, 2012. ISBN: 978-1-4614-100-3.
3. Thompson TC, Kadmon D, Arnall MF, Flanagan WF, Egawa S, Scardino PT, Park S and Merz VW. Evidence for the involvement of genetic differences and mesenchymal factors in the progression of oncogene-induced prostate cancer in reconstituted mouse prostate. In: Molecular and Cellular Biology of Prostate Cancer. Ed(s) Karr JP, Smith RG, Tindall DJ and Coffey DS. Plenum Press: New York, 1991.

Grant & Contract Support

Title: MD Anderson Cancer Center Prostate Cancer SPORE – Project 3: Targeting Androgen Receptor and PARP for Synthetic Lethality in CRPC
Funding Source: NIH/NCI
Role: Basic Co-Leader
Principal Investigator: Logothetis/Thompson (MPI)
Duration: 4/1/2016 - 3/31/2021
 
Title: MD Anderson Cancer Center Prostate Cancer SPORE – Administrative Core
Funding Source: NIH/NCI
Role: Core Director
Principal Investigator: Logothetis/Thompson (MPI)
Duration: 4/1/2016 - 3/31/2021
 
Title: MD Anderson Cancer Center Prostate Cancer SPORE – Developmental Research Program
Funding Source: NIH/NCI
Role: Director
Principal Investigator: Logothetis/Thompson (MPI)
Duration: 4/1/2016 - 3/31/2021
 
Title: Prostate Cancer Moon Shot: Integrated Plan for Reducing Mortality of Advanced Prostate Cancer
Funding Source: MD Anderson Moon Shot Program
Role: Co-Principal Investigator
Principal Investigator: Logothetis/Thompson
Duration: 9/1/2015 - 8/31/2016
 
Title: Development of Predictive Biomarker for Therapeutic Response of Aggressive Variant Prostate Cancer
Funding Source: MD Anderson Moon Shot
Role: Principal Investigator
Duration: 2/1/2015 - 1/19/2017
 
Title: Cancer Center Support (CORE) Grant-RP-16 Prostate and Genitourinary Program
Funding Source: NIH/NCI
Role: Co-Leader, GU Cancers Program
Principal Investigator: Ronald DePinho
Duration: 7/1/2008 - 6/30/2018

Last updated: 8/9/2016